ReviewFrontiers in pharmacology2023
Therapeutic effects on cancer of the active ingredients in rhizoma paridis.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Rhizoma Paridis saponins in respiratory diseases: a narrative review of multi-target mechanisms and therapeutic potential.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Enhancing Targeted Colorectal Cancer Therapies with Natural Products: Mechanistic Pathways.Biomedicines · 2026Review
- Multi-omics identification of therapeutic targets of compound sappan decoction in hepatocellular carcinoma.Discover oncology · 2026Article
- The Mechanisms of Ramulus Cinnamomi and Rhizoma Paridis in Gynecological Cancers: A Narrative Review.Cancer management and research · 2026Review
- The Multitalented Marvels: Exploring the Versatile Potential of Natural Products in Osteosarcoma Treatment.Cancer informatics · 2026Review
- [Polyphyllin VII inhibits osteosarcoma xenograft growth in mice by inducing ferroptosisNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- A novel biomimetic nanoplatform amplifies ferroptosis for specific cGAS-STING pathway activation to enhance hepatocellular carcinoma chemo-immunotherapy.Journal of nanobiotechnology · 2025Article
- Polyphyllin H Reverses Paclitaxel Resistance in Breast Cancer by Binding Membrane Cholesterol to Inhibit Both ABCB1 and ABCC3.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Research Progress and Prospects of Saponins in the Treatment of NAFLD: A Narrative Review.Molecules (Basel, Switzerland) · 2025Review
- Repurposing Suan-Zao-Ren-Tang as anticancer agents in apoptotic sensitization against non-small cell lung cancer cell lines through amplification of spindle assembly checkpoint activation.Journal of traditional and complementary medicine · 2025Article
- Progress of traditional Chinese medicine in the prevention and treatment of colorectal cancer.World journal of gastrointestinal oncology · 2025Review
- Polyphyllin I inhibits ovarian cancer growth by inducing G0/G1 phase arrest and inhibiting the c-Myc signaling pathway.Medical oncology (Northwood, London, England) · 2025Article
- Exploration of the mechanism of Polyphyllin I against hepatocellular carcinoma based on network pharmacology, molecular docking and experimental validation.Discover oncology · 2025Article
- Polyphyllin I Inhibits the Metastasis of Cervical Cancer Through the Regulation of the β-Catenin Signaling Pathway.International journal of molecular sciences · 2025Article
- Polyphyllin VII enhances the sensitivity of endometrial carcinoma cells to medroxyprogesterone acetate through upregulating miR‑33a‑5p expression.Oncology letters · 2025Article
- Exploring the toxicity mechanisms and detoxification methods of Rhizoma Paridis.Open life sciences · 2025Review
- SORBS1 Knockdown Resists S/G2 Arrest and Apoptosis Caused by Polyphyllin H-Induced DNA Damage in Pancreatic Cancer.Oncology research · 2025Article
- Polyphyllin II inhibits thyroid cancer cell growth by simultaneously inhibiting glycolysis and oxidative phosphorylation.Open medicine (Warsaw, Poland) · 2025Article
- Polyphyllin II inhibits breast cancer cell proliferation via the PI3K/Akt signaling pathway.Molecular medicine reports · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a major threat to human health, with high mortality and a low cure rate, continuously challenging public health worldwide. Extensive clinical application of traditional Chinese medicine (TCM) for patients with poor outcomes of radiotherapy and chemotherapy provides a new direction in anticancer therapy. Anticancer mechanisms of the active ingredients in TCM have also been extensively studied in the medical field. As a type of TCM against cancer, Rhizoma Paridis (Chinese name: Chonglou) has important antitumor effects in clinical application. The main active ingredients of Rhizoma Paridis (e.g., total saponins, polyphyllin I, polyphyllin II, polyphyllin VI, and polyphyllin VII) have shown strong antitumor activities in various cancers, such as breast cancer, lung cancer, colorectal cancer, hepatocellular carcinoma (HCC), and gastric cancer. Rhizoma Paridis also has low concentrations of certain other active ingredients with antitumor effects, such as saponins polyphyllin E, polyphyllin H,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.